Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Blin

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
Annals of Hematology|June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experienceJ Bourcier, T Gastinne, C Leux, et al.
Leukemia|February 26, 2011
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantationZ Peric, X Cahu, P Chevallier, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
Annals of Hematology|June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experienceJ Bourcier, T Gastinne, C Leux, et al.
Leukemia|February 26, 2011
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantationZ Peric, X Cahu, P Chevallier, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Pageof 16